Dr.Reddy's Laboratories informs about press release

19 Dec 2022 Evaluate
Dr.Reddy's Laboratories has informed that it enclosed Press Release titled 'Dr. Reddy's successfully completes Phase 1 study of DRL_TC, a proposed biosimilar of tocilizumab’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1251.40 -19.65 (-1.55%)
01-Jan-2026 10:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.15
Dr. Reddys Lab 1251.40
Cipla 1503.05
Zydus Lifesciences 908.55
Lupin 2083.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×